{"title":"Growing the intense inhibitor class--Elvitegravir and Dolutegravir.","authors":"C. Hicks","doi":"10.1056/AC201112300000010","DOIUrl":null,"url":null,"abstract":"Four years have passed since the licensing of the first HIV integrase inhibitor, raltegravir, and the drug has proven to be both effective and well","PeriodicalId":88277,"journal":{"name":"Journal watch. AIDS clinical care","volume":"93 1","pages":"5-6"},"PeriodicalIF":0.0000,"publicationDate":"2011-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal watch. AIDS clinical care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1056/AC201112300000010","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Four years have passed since the licensing of the first HIV integrase inhibitor, raltegravir, and the drug has proven to be both effective and well
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
